Home Tags HR+/HER2- metastatic breast cancer

Tag: HR+/HER2- metastatic breast cancer

US FDA Approves Sacituzumab Govitecan In Pre-treated HR+/HER2- Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

X